Benzinga | Aug 26, 2021 09:02AM EDT

BD Locks FDA Emergency Use Nod For At-Home COVID-19 Antigen Test

* The FDA has issued an Emergency Use Authorization (EUA) for Becton Dickinson and Co's (NYSE:BDX) BD Veritor At-Home COVID-19 Test.

* Also Read: BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV

* The at-home COVID-19 rapid antigen test uses computer vision technology in a smartphone to interpret and provide a digital display of testing results.

* It does not require a prescription, a laboratory, or a long wait for results.

* The test will initially be made available to businesses, schools, and governments looking to provide a self-testing option for employees or students.

* The BD Veritor At-Home COVID-19 Test will use a simple, pain-free nasal swab and an easy-to-use mobile app from Scanwell Health that yields reliable test results in 15 minutes.

* The app is available on iOS and Android. The test can also be used for children as young as two years old with samples collected by an adult.

* Related content: Benzinga's Full FDA Calendar

* Price Action: BDX shares closed 0.35% lower at $247 on Wednesday.